September 19, 2016
Three decades of polio eradication efforts in India has saved more than 390,000 lives, averted nearly 4 million cases of paralysis and boosted productivity by US$1.71 trillion
CDDEP-contributed research published in Indian Pediatrics has examined the health and economic benefits of three decades of polio eradication efforts in India, estimating that India has averted 3.94 million paralytic cases of polio, 393,918 related deaths, and 1.48 billion disability-adjusted life-years (DALYs). As a result of eradication efforts, India has also gained US$1.71 trillion in economic productivity between 1982 and 2012, according to the study’s base case analysis.
Over three decades, the Indian government has apportioned nearly US$2 billion through various initiatives, including the Expanded Programme on Immunization (EPI), the Universal Immunization Programme, the National Polio Surveillance Project and the Pulse Polio Programme (PPP). The National Polio Surveillance Project (NPSP) and Pulse Polio Program (PPP) together have administered an estimated 12.1 billion doses of the oral polio vaccine. India was officially declared polio free in 2014.
According to lead author Arindam Nandi, “India has made great contributions toward the global eradication of polio and the results are clear. Quantifying the health and economic benefits of polio elimination in India can help researchers and policymakers understand the benefits of large-scale immunization programs and what could be gained if polio is eradicated from the remaining endemic countries.”
The article in Indian Pediatrics is available here: http://www.indianpediatrics.net/supplaug2016/s7.pdf
About the Center for Disease Dynamics, Economics & Policy
The Center for Disease Dynamics, Economics & Policy (CDDEP) produces independent, multidisciplinary research to advance the health and wellbeing of human populations around the world. CDDEP projects are global in scope, spanning Africa, Asia, and North America and include scientific studies and policy engagement. The CDDEP team is experienced in addressing country-specific and regional issues, as well as the local and global aspects of global challenges, such as antibiotic resistance and pandemic influenza. CDDEP research is notable for innovative approaches to design and analysis, which are shared widely through publications, presentations and web-based programs. CDDEP has offices in Washington, D.C. and New Delhi and relies on a distinguished team of scientists, public health experts and economists.
Authors: Arindam Nandi, Devra M. Barter, Shankar Prinja, T. Jacob John